TR1801-ADC in Patients With Tumors That Express c-Met
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Gilad Gordon, MD
Open Innovation Partners
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of Southern California Norris Comprehensive Cancer Center
Los Angeles, California, United States
- University of Colorado
Aurora, Colorado, United States
- John Hopkins - Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, United States
- University of Washington / Seattle Cancer Care
Seattle, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 14 Aug 2019
- Primary completion
- 4 Jul 2023
- Completion
- 31 Dec 2023
- Last update posted
- 22 Sept 2023
- Registered enrollment
- 15
- Registry id
- NCT03859752
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 11 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.